WO1999006043A1 - Self-emulsifying formulation for lipophilic compounds - Google Patents
Self-emulsifying formulation for lipophilic compounds Download PDFInfo
- Publication number
- WO1999006043A1 WO1999006043A1 PCT/US1998/014816 US9814816W WO9906043A1 WO 1999006043 A1 WO1999006043 A1 WO 1999006043A1 US 9814816 W US9814816 W US 9814816W WO 9906043 A1 WO9906043 A1 WO 9906043A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- weight
- amount
- diglyceride
- monoglyceride
- Prior art date
Links
- SUJUHGSWHZTSEU-BRUPJXTFSA-N CCC[C@@](CCc1ccccc1)(CC(O)=C1C(CC)c2cc(NS(c3ccc(C(F)(F)F)cn3)(=O)=O)ccc2)OC1=O Chemical compound CCC[C@@](CCc1ccccc1)(CC(O)=C1C(CC)c2cc(NS(c3ccc(C(F)(F)F)cn3)(=O)=O)ccc2)OC1=O SUJUHGSWHZTSEU-BRUPJXTFSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2000-7000943A KR100509130B1 (en) | 1997-07-29 | 1998-07-27 | Self-Emulsifying Formulation for Lipophilic Compounds |
SK18-2000A SK284579B6 (en) | 1997-07-29 | 1998-07-27 | Pharmaceutical composition for lipophilic compounds |
AU85737/98A AU728695B2 (en) | 1997-07-29 | 1998-07-27 | Self-emulsifying formulation for lipophilic compounds |
BRPI9810866-2A BR9810866B1 (en) | 1997-07-29 | 1998-07-27 | pharmaceutical composition in a self-emulsifying formulation form for lipophilic compounds. |
DE69804624T DE69804624T2 (en) | 1997-07-29 | 1998-07-27 | SELF-TEMPERATURE FORMULATION CONTAINING LIPOPHILE COMPOUNDS |
DK98936887T DK0999838T3 (en) | 1997-07-29 | 1998-07-27 | Self-emulsifying formulation for lipophilic compounds |
AT98936887T ATE215370T1 (en) | 1997-07-29 | 1998-07-27 | SELF-EMULSIFYING FORMULATION CONTAINING LIPOPHILIC COMPOUNDS |
HU0003292A HU225160B1 (en) | 1997-07-29 | 1998-07-27 | Self-emulsifying formulation for lipophilic compounds |
NZ502567A NZ502567A (en) | 1997-07-29 | 1998-07-27 | Self-emulsifying formulation for lipophilic compounds containing a pyranone and a mixture of monoglycerides and diglycerides |
JP51097299A JP5005847B2 (en) | 1997-07-29 | 1998-07-27 | Self-emulsifying formulation for lipophilic compounds |
PL338334A PL192080B1 (en) | 1997-07-29 | 1998-07-27 | Pharmaceutic composition in the form of self-emulsifiable formulation of lipophilic compounds |
CA002294032A CA2294032A1 (en) | 1997-07-29 | 1998-07-27 | Self-emulsifying formulation for lipophilic compounds |
SI9830188T SI0999838T1 (en) | 1997-07-29 | 1998-07-27 | Self-emulsifying formulation for lipophilic compounds |
EP98936887A EP0999838B1 (en) | 1997-07-29 | 1998-07-27 | Self-emulsifying formulation for lipophilic compounds |
FI20000171A FI20000171A (en) | 1997-07-29 | 2000-01-28 | Pharmaceutical composition in the form of a self-emulsifying preparation for lipophilic compounds |
NO20000465A NO323773B1 (en) | 1997-07-29 | 2000-01-28 | A pharmaceutical composition comprising a pyranone compound |
HK00108278A HK1028877A1 (en) | 1997-07-29 | 2000-12-21 | Self-emulsifying formulation for lipophilic compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5407897P | 1997-07-29 | 1997-07-29 | |
US60/054,078 | 1997-07-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999006043A1 true WO1999006043A1 (en) | 1999-02-11 |
Family
ID=21988649
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/014816 WO1999006043A1 (en) | 1997-07-29 | 1998-07-27 | Self-emulsifying formulation for lipophilic compounds |
Country Status (23)
Country | Link |
---|---|
US (2) | US6531139B1 (en) |
EP (1) | EP0999838B1 (en) |
JP (1) | JP5005847B2 (en) |
KR (1) | KR100509130B1 (en) |
CN (1) | CN1113650C (en) |
AT (1) | ATE215370T1 (en) |
AU (1) | AU728695B2 (en) |
BR (1) | BR9810866B1 (en) |
CA (1) | CA2294032A1 (en) |
DE (1) | DE69804624T2 (en) |
DK (1) | DK0999838T3 (en) |
ES (1) | ES2174462T3 (en) |
FI (1) | FI20000171A (en) |
HK (1) | HK1028877A1 (en) |
HU (1) | HU225160B1 (en) |
NO (1) | NO323773B1 (en) |
NZ (1) | NZ502567A (en) |
PL (1) | PL192080B1 (en) |
PT (1) | PT999838E (en) |
RU (1) | RU2203648C2 (en) |
SI (1) | SI0999838T1 (en) |
SK (1) | SK284579B6 (en) |
WO (1) | WO1999006043A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000057885A1 (en) * | 1999-03-31 | 2000-10-05 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
WO2001068139A1 (en) * | 2000-03-13 | 2001-09-20 | Korea Institute Of Science And Technology | Formulation solubilizing water-insoluble agents and preparation method thereof |
WO2002036110A2 (en) * | 2000-10-31 | 2002-05-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Oral self-emulsifying formulations of pyranone protease inhibitors |
WO2002064166A1 (en) * | 2001-02-13 | 2002-08-22 | Korea Institute Of Science And Technology | Formulation to enhance bioavailability of bioactive matrials and preparation method thereof |
WO2003105607A1 (en) * | 2002-06-12 | 2003-12-24 | Nutralease Ltd. | Nano-sized self-assembled structured liquids |
WO2005077336A1 (en) * | 2004-02-12 | 2005-08-25 | Korea Institute Of Science And Technology | Composition and formulation of colloidal system comprising biocompatible aqueous-soluble polymer, and preparation method thereof |
US6956048B2 (en) | 1999-03-31 | 2005-10-18 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
WO2012010942A3 (en) * | 2010-07-22 | 2012-05-24 | Lupin Limited | Novel pharmaceutical composition(s) of hiv protease inhibitor(s) |
US8575147B2 (en) | 1999-02-16 | 2013-11-05 | Novartis Ag | Spontaneously dispersible N-benzoyl staurosporine compositions |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI0999826T1 (en) * | 1997-07-29 | 2004-12-31 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
US7135191B2 (en) * | 1997-09-04 | 2006-11-14 | Zsolt Istvan Hertelendy | Urogenital or anorectal transmucosal vaccine delivery system |
US6248363B1 (en) * | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20030236236A1 (en) * | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
GB9925127D0 (en) * | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
FR2805761B1 (en) * | 2000-03-02 | 2002-08-30 | Mainelab | LIPID NANOCAPSULES, METHOD OF PREPARATION AND USE AS A MEDICAMENT |
US6623765B1 (en) * | 2000-08-01 | 2003-09-23 | University Of Florida, Research Foundation, Incorporated | Microemulsion and micelle systems for solubilizing drugs |
US6680470B1 (en) * | 2001-11-14 | 2004-01-20 | Dicon Fiberoptics, Inc. | Interleaver with thermal and chromatic dispersion compensation |
JP2005515187A (en) * | 2001-11-26 | 2005-05-26 | スーパージェン インコーポレイテッド | Process for the preparation of pharmaceutical compositions using polyoxyethylated castor oil |
EA008072B1 (en) * | 2001-12-03 | 2007-02-27 | Новацея, Инк. | Pharmaceutical compositions comprising active vitamin d compounds |
US20030165545A1 (en) * | 2002-01-30 | 2003-09-04 | Allergan, Inc. | Ophthalmic compositions including oil-in-water emulsions, and methods for making and using same |
US6828301B2 (en) * | 2002-02-07 | 2004-12-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for hepatitis C viral protease inhibitors |
US20030199584A1 (en) * | 2002-04-11 | 2003-10-23 | Ahluwalia Gurpreet S. | Reduction of hair growth |
KR100533458B1 (en) * | 2002-07-20 | 2005-12-07 | 대화제약 주식회사 | Composition for solubilization of paclitaxel and preparation method thereof |
US20050026877A1 (en) * | 2002-12-03 | 2005-02-03 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
US20060251685A1 (en) * | 2003-03-18 | 2006-11-09 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye |
US20040185068A1 (en) * | 2003-03-18 | 2004-09-23 | Zhi-Jian Yu | Self-emulsifying compositions, methods of use and preparation |
US20050196370A1 (en) * | 2003-03-18 | 2005-09-08 | Zhi-Jian Yu | Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye |
US20040191332A1 (en) * | 2003-03-27 | 2004-09-30 | Allergan, Inc. | Preserved ophthalmic compositions |
US20050020546A1 (en) * | 2003-06-11 | 2005-01-27 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin D compounds |
US20060003002A1 (en) * | 2003-11-03 | 2006-01-05 | Lipocine, Inc. | Pharmaceutical compositions with synchronized solubilizer release |
GB0402679D0 (en) * | 2004-02-06 | 2004-03-10 | Novartis Ag | Organic compounds |
CA2632149C (en) * | 2005-12-01 | 2011-11-15 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
WO2008058234A2 (en) * | 2006-11-08 | 2008-05-15 | Memory Pharmaceuticals Corporation | Pharmaceutical formulations for 1,4-dihyrdropyridine compounds having improved solubility |
US20100093749A1 (en) * | 2007-03-09 | 2010-04-15 | Novartis Ag | Compounds |
WO2008142090A1 (en) * | 2007-05-23 | 2008-11-27 | Boehringer Ingelheim International Gmbh | Self-emulsifying formulation of tipranavir for oral administration |
HU227873B1 (en) * | 2007-06-18 | 2012-05-29 | Biogreen As | Emulsions based of plant-germ, process for their production and use |
NZ581589A (en) * | 2007-06-22 | 2012-10-26 | Scidose Llc | Solubilized sterile injectable formulation of docetaxel without Tween 80 |
US9180088B2 (en) | 2008-03-07 | 2015-11-10 | Scidose, Llc | Fulvestrant formulations |
EP2257220B1 (en) * | 2008-03-13 | 2017-06-14 | Liebel-Flarsheim Company LLC | Multi-function, foot-activated controller for imaging system |
US20110275717A1 (en) * | 2008-11-28 | 2011-11-10 | Advance Holdings Limited | Pharmaceutical formulation comprising diclofenac |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
MX2011013824A (en) | 2009-07-07 | 2012-01-30 | Boehringer Ingelheim Int | Pharmaceutical composition for a hepatitis c viral protease inhibitor. |
WO2011047259A1 (en) | 2009-10-16 | 2011-04-21 | Glaxosmithkline Llc | Compositions |
US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
TWI438009B (en) * | 2010-02-19 | 2014-05-21 | Teikoku Pharma Usa Inc | Taxane pro-emulsion formulations and methods making and using the same |
SG185389A1 (en) | 2010-05-03 | 2012-12-28 | Teikoku Pharma Usa Inc | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
WO2012039768A2 (en) * | 2010-09-24 | 2012-03-29 | Texas Southern University | Itraconazole formulations |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
US11179468B2 (en) | 2012-04-09 | 2021-11-23 | Eagle Pharmaceuticals, Inc. | Fulvestrant formulations |
JO3685B1 (en) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | Non-aqueous taxane nanodispersion formulations and methods of using the same |
US10711238B2 (en) | 2012-10-02 | 2020-07-14 | Repligen Corporation | Method for proliferation of cells within a bioreactor using a disposable pumphead and filter assembly |
WO2014128564A2 (en) | 2013-02-21 | 2014-08-28 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of cetp inhibitors |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
WO2016033549A2 (en) | 2014-08-28 | 2016-03-03 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
EP3248599B1 (en) * | 2015-01-21 | 2022-07-06 | Mochida Pharmaceutical Co., Ltd. | Omega-3 fatty acid self-emulsifying composition |
KR101994129B1 (en) | 2015-05-28 | 2019-06-28 | 닥터 레디스 레보러터리즈 리미티드 | Celecoxib oral composition for pain treatment |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
BR112018070199A2 (en) | 2016-04-01 | 2019-01-29 | Therapeuticsmd Inc | pharmaceutical composition of steroid hormone |
JP2020503269A (en) | 2016-11-28 | 2020-01-30 | リポカイン インコーポレーテッド | Oral testosterone undecanoate therapy |
TWI676824B (en) | 2019-01-09 | 2019-11-11 | 友達光電股份有限公司 | Display device and display method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0267617A1 (en) * | 1986-11-14 | 1988-05-18 | Theratech, Inc. | Penetration enhancement with binary system of cell envelope disordering compounds and lower alcohols |
WO1998022106A1 (en) * | 1996-11-21 | 1998-05-28 | Abbott Laboratories | Pharmaceutical composition |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4230702A (en) | 1978-01-09 | 1980-10-28 | Kali-Chemie Pharma Gmbh | Readily enterally absorbable pharmaceutical compositions of per se poorly enterally absorbable pharmacologically active agents |
JPS5618914A (en) * | 1979-07-25 | 1981-02-23 | Eisai Co Ltd | Ubidecarenone composition having good absorbability |
GB8903804D0 (en) * | 1989-02-20 | 1989-04-05 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5639724A (en) * | 1984-07-24 | 1997-06-17 | Sandoz Ltd. | Cyclosporin galenic forms |
JPH0629180B2 (en) * | 1986-06-16 | 1994-04-20 | エーザイ株式会社 | Compositions containing menatetrenone with improved absorption |
DE3629386A1 (en) * | 1986-08-29 | 1988-03-03 | Scherer Gmbh R P | GELATINE CAPSULES AND METHOD FOR THEIR PRODUCTION |
JP2632010B2 (en) * | 1988-01-29 | 1997-07-16 | 三共株式会社 | Cyclosporine preparation |
KR0148748B1 (en) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | A multiphase cyclosporin composition |
IL102236A0 (en) * | 1991-06-27 | 1993-01-14 | Ltt Inst Co Ltd | Topical preparations containing cyclosporin |
GB9113872D0 (en) * | 1991-06-27 | 1991-08-14 | Sandoz Ag | Improvements in or relating to organic compounds |
ES2168271T3 (en) * | 1992-09-25 | 2002-06-16 | Novartis Ag | PHARMACEUTICAL COMPOSITIONS CONTAINING CYCLOSPORINS. |
JPH08502490A (en) * | 1992-10-16 | 1996-03-19 | スミスクライン・ビーチャム・コーポレイション | Composition |
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
IL129871A (en) | 1994-05-06 | 2003-11-23 | Pharmacia & Upjohn Inc | Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections |
MX9709193A (en) | 1995-06-06 | 1998-03-31 | Hoffmann La Roche | Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride. |
DE19537012A1 (en) * | 1995-10-04 | 1997-04-10 | Dietl Hans | Pharmaceutical preparation containing cyclosporin (s) for oral administration and process for its preparation |
SI0999826T1 (en) * | 1997-07-29 | 2004-12-31 | Pharmacia & Upjohn Company | Self-emulsifying formulation for lipophilic compounds |
-
1998
- 1998-07-27 DE DE69804624T patent/DE69804624T2/en not_active Expired - Lifetime
- 1998-07-27 HU HU0003292A patent/HU225160B1/en not_active IP Right Cessation
- 1998-07-27 CA CA002294032A patent/CA2294032A1/en not_active Abandoned
- 1998-07-27 RU RU2000104872/14A patent/RU2203648C2/en not_active IP Right Cessation
- 1998-07-27 PT PT98936887T patent/PT999838E/en unknown
- 1998-07-27 WO PCT/US1998/014816 patent/WO1999006043A1/en not_active Application Discontinuation
- 1998-07-27 ES ES98936887T patent/ES2174462T3/en not_active Expired - Lifetime
- 1998-07-27 KR KR10-2000-7000943A patent/KR100509130B1/en not_active IP Right Cessation
- 1998-07-27 US US09/122,926 patent/US6531139B1/en not_active Expired - Lifetime
- 1998-07-27 AU AU85737/98A patent/AU728695B2/en not_active Ceased
- 1998-07-27 DK DK98936887T patent/DK0999838T3/en active
- 1998-07-27 EP EP98936887A patent/EP0999838B1/en not_active Expired - Lifetime
- 1998-07-27 CN CN98806772A patent/CN1113650C/en not_active Expired - Fee Related
- 1998-07-27 SK SK18-2000A patent/SK284579B6/en unknown
- 1998-07-27 PL PL338334A patent/PL192080B1/en unknown
- 1998-07-27 JP JP51097299A patent/JP5005847B2/en not_active Expired - Fee Related
- 1998-07-27 SI SI9830188T patent/SI0999838T1/en unknown
- 1998-07-27 BR BRPI9810866-2A patent/BR9810866B1/en not_active IP Right Cessation
- 1998-07-27 US US09/123,069 patent/US6121313A/en not_active Expired - Lifetime
- 1998-07-27 NZ NZ502567A patent/NZ502567A/en not_active IP Right Cessation
- 1998-07-27 AT AT98936887T patent/ATE215370T1/en active
-
2000
- 2000-01-28 FI FI20000171A patent/FI20000171A/en unknown
- 2000-01-28 NO NO20000465A patent/NO323773B1/en not_active IP Right Cessation
- 2000-12-21 HK HK00108278A patent/HK1028877A1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0267617A1 (en) * | 1986-11-14 | 1988-05-18 | Theratech, Inc. | Penetration enhancement with binary system of cell envelope disordering compounds and lower alcohols |
WO1998022106A1 (en) * | 1996-11-21 | 1998-05-28 | Abbott Laboratories | Pharmaceutical composition |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8722664B2 (en) | 1999-02-16 | 2014-05-13 | Novartis Ag | Spontaneously dispersible N-benzoyl staurosporine compositions |
US8575147B2 (en) | 1999-02-16 | 2013-11-05 | Novartis Ag | Spontaneously dispersible N-benzoyl staurosporine compositions |
US6956048B2 (en) | 1999-03-31 | 2005-10-18 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
WO2000057885A1 (en) * | 1999-03-31 | 2000-10-05 | Pharmacia & Upjohn Company | Pharmaceutical emulsions for retroviral protease inhibitors |
WO2001068139A1 (en) * | 2000-03-13 | 2001-09-20 | Korea Institute Of Science And Technology | Formulation solubilizing water-insoluble agents and preparation method thereof |
US6994862B2 (en) | 2000-03-13 | 2006-02-07 | Korea Institute Of Science And Technology | Formulation solubilizing water-insoluble agents and preparation method thereof |
AU777347B2 (en) * | 2000-03-13 | 2004-10-14 | Korea Institute Of Science And Technology | Formulation solubilizing water-insoluble agents and preparation method thereof |
WO2002036110A3 (en) * | 2000-10-31 | 2003-05-08 | Boehringer Ingelheim Pharma | Oral self-emulsifying formulations of pyranone protease inhibitors |
AU2002230918B2 (en) * | 2000-10-31 | 2006-12-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Oral self-emulsifying formulations of pyranone protease inhibitors |
KR100847679B1 (en) * | 2000-10-31 | 2008-07-23 | 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 | Oral dosage self-emulsifying formulations of pyranone protease inhibitors |
WO2002036110A2 (en) * | 2000-10-31 | 2002-05-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Oral self-emulsifying formulations of pyranone protease inhibitors |
WO2002064166A1 (en) * | 2001-02-13 | 2002-08-22 | Korea Institute Of Science And Technology | Formulation to enhance bioavailability of bioactive matrials and preparation method thereof |
WO2003105607A1 (en) * | 2002-06-12 | 2003-12-24 | Nutralease Ltd. | Nano-sized self-assembled structured liquids |
US7182950B2 (en) | 2002-06-12 | 2007-02-27 | Nutralease Ltd. | Nano-sized self-assembled liquid dilutable vehicles |
WO2005077336A1 (en) * | 2004-02-12 | 2005-08-25 | Korea Institute Of Science And Technology | Composition and formulation of colloidal system comprising biocompatible aqueous-soluble polymer, and preparation method thereof |
WO2012010942A3 (en) * | 2010-07-22 | 2012-05-24 | Lupin Limited | Novel pharmaceutical composition(s) of hiv protease inhibitor(s) |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0999838B1 (en) | Self-emulsifying formulation for lipophilic compounds | |
EP0989851B1 (en) | Self-emulsifying formulation for acidic lipophilic compounds | |
AU728698B2 (en) | Self-emulsifying formulation for lipophilic compounds | |
US20030044434A1 (en) | Self-emulsifying formulation for lipophilic compounds | |
MXPA00000996A (en) | Self-emulsifying formulation for lipophilic compounds | |
MXPA00000995A (en) | Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation | |
CZ2000158A3 (en) | Pharmaceutical composition in the form of self-emulsifying formulation for lipophilic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98806772.2 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2294032 Country of ref document: CA Ref document number: 2294032 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998936887 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 182000 Country of ref document: SK |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-158 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 85737/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/000996 Country of ref document: MX Ref document number: 1020007000943 Country of ref document: KR Ref document number: 20000171 Country of ref document: FI Ref document number: 502567 Country of ref document: NZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1998936887 Country of ref document: EP Ref document number: PV2000-158 Country of ref document: CZ |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007000943 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 85737/98 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998936887 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1020007000943 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2000-158 Country of ref document: CZ |